Boehringer Ingelheim welcomes the opportunity to input into this consultation. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective and stands for continuous investment in medical innovation to improve the health of humans and animals. As a research-driven biopharmaceutical company, our patient-centric research focus lies on areas of high unmet medical need.
BI
Boehringer Ingelheim
Company · Germany · EU Transparency Register 289777818743-24
8
positions filed
in the 665 files tracked
8
legislative files
of 665 tracked
4
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #184 by legislative files engaged, a count of participation, not a measure of influence.
2
declared lobbying FTE
self-declared
€2M+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- The following is a list of the main associations of which Boehringer is an active member:
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- AnimalhealthEurope →
- International Pharmaceutical Aerosol Consortium (IPAC)
- European Animal Research Association (EARA)
- Verband der Chemischen Industrie (VCI)
- EU-ASEAN Business Council
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Head office
- Ingelheim, Germany
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Boehringer in PolicySpeak: request access →
Work at Boehringer Ingelheim? so we know who speaks for it.
Their record over time
Boehringer Ingelheim filed 8 positions between 9 Dec 2020 and 19 May 2026, across 8 of the 665 legislative files tracked here, attaching a full position paper 4 times.
2020 · 2 filed2021 · 2 filed2022 · 2 filed2025 · 1 filed2026 · 1 filed
What they argued
Boehringer Ingelheim is a leading research-driven biopharmaceutical company committed to advancing human and animal health. As one of the industrys top global investors in R&D, we focus on developing innovative therapies that address areas of high unmet medical need, improving and extending lives worldwide.
Boehringer Ingelheim (BI) welcomes the European Commission’s ambition to reduce the use of substances with Global Warming Potential (GWP) and to comply with recent international obligations on HFCs (Montreal Protocol).
CVD remains the leading cause of mortality in the EU, yet a substantial share of risk factors and underlying conditions remain undetected. Early CVD detection efforts must better reflect the interconnected nature of cardiovascular, renal and metabolic (CRM) conditions, which frequently co-exist, amplify one another, and significantly increase the risk of adverse outcomes.
Family-owned since it was established in 1885, Boehringer Ingelheim (BI) pursues a long-term vision and stands for continuous investment in medical innovation to improve the health and quality of life of humans and animals.
Family-owned since it was established in 1885, Boehringer Ingelheim pursues a long-term vision and stands for continuous investment in medical innovation to improve the health and quality of life of humans and animals. We welcome the opportunity to input into this consultation and urge the EU Commission (EC) to consider the below industry view put forward by EFPIA.
Dear ladies and gentlemen, Boehringer Ingelheim welcomes the opportunity to provide feedback regarding the European Commission’s consultation regarding a draft implementing decision on Standard Contractual Clauses for the transfer of personal data to third countries pursuant to Regulation (EU) 2016/679 of the European Parliament and of the Council as set forth in the atteched document.
Dear ladies and gentlemen, Boehringer Ingelheim welcomes the opportunity to provide feedback regarding the European Commission’s consultation regarding a draft implementing decision on Standard Contractual Clauses for the transfer of personal data to third countries pursuant to Regulation (EU) 2016/679 of the European Parliament and of the Council” set forth in the attached document.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Boehringer Ingelheim next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 130.
Is this your organization?
Everything on this page comes from Boehringer Ingelheim’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.